학제간연구 | Interdisciplinary Studies in Gambling | 跨学科研究
- date : 2015-05-20 01:10|hit : 1858
-
- Review] Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome
-
DocNo of ILP: 4141
Doc. Type: Review
Title: Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome
Authors: Driver-Dunckley, ED; Noble, BN; Hentz, JG; Evidente, VGH; Caviness, JX; Parish, J; Krabn, L; Adler, CH
Full Name of Authors: Driver-Dunckley, Erika D.; Noble, Brie N.; Hentz, Joseph G.; Evidente, Virgilio G. H.; Caviness, John X.; Parish, James; Krabn, Lois; Adler, Charles H.
Keywords by Author: gambling; RLS; dopaminergic drugs
Keywords Plus: HEDONISTIC HOMEOSTATIC DYSREGULATION; PARKINSONS-DISEASE; REPLACEMENT THERAPY; ASSOCIATION; DEPRESSION; SYMPTOMS; DISORDER; ANXIETY; REWARD
Abstract: Objectives: Do patients with restless legs syndrome (RLS) report gambling or other abnormal behaviors as previously reported in Parkinson disease. Methods: This survey study was sent to 261 idiopathic RLS patients, and it included the Gambling Symptoms Assessment Scale, Altman Self-Rating Mania Scale, and questions pertaining to sexual activity and novelty-seeking behaviors. Results: Ninety-nine patients responded to the survey, and 77 were actively taking 1 or more dopaminergic medications. Of the 70 respondents who answered the gambling questions, 5 (7%) noted a change in gambling, with 4 (6%; 95% confidence interval, 2%-14%) stating that increased urges and time spent gambling occurred specifically after the use of dopaminergic medications (2 on pramipexole, I on ropinirole, and I on levodopa and pramipexole). Increased sexual desire was reported by 4 (5%) of the 77 respondents, 3 (4%; 95% confidence interval, 1%-11%) reported that this occurred specifically after the use of dopaminergic medications (1 on pramipexole, I on ropinirole, and I on levodopa). One patient reported both an increase in gambling and sexual habits. Conclusions: This exploratory survey study revealed the development of gambling and/or increased sexuality in patients with RLS. These data raise the possibility that, as in Parkinson disease, RLS patients should be cautioned about potential behaviors that may occur with the use of dopaminergic medications. Further prospective studies are needed to assess the relationship between these medications and compulsive behaviors associated with the treatment of RLS.
Cate of OECD: Clinical medicine
Year of Publication: 2007
Business Area: gamble
Detail Business: gamble
Country: USA
Study Area:
Name of Journal: CLINICAL NEUROPHARMACOLOGY
Language: English
Country of Authors: Parkinsons Dis & Movement Disorders Ctr, Dept Neurol, Mayo Clin, Scottsdale, AZ 85259 USA; Mayo Clin, Biostat Sect, Scottsdale, AZ USA; Mayo Clin, Sleep Disorders Div, Scottsdale, AZ USA
Press Adress: Driver-Dunckley, ED (reprint author), Parkinsons Dis & Movement Disorders Ctr, Dept Neurol, Mayo Clin, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.
Email Address: driverdunckley.erika@mayo.edu
Citaion:
Funding:
Lists of Citation: Alegret M, 2001, J NEUROL NEUROSUR PS, V70, P394, DOI 10.1136/jnnp.70.3.394; Altman EG, 1997, BIOL PSYCHIAT, V42, P948, DOI 10.1016/S0006-3223(96)00548-3; Avanzi M, 2004, NEUROL SCI, V25, P98, DOI 10.1007/s10072-004-0238-z; Cannas A, 2002, NEUROL SCI, V23, pS67, DOI 10.1007/s100720200073; Dodd ML, 2005, ARCH NEUROL-CHICAGO, V62, P1377, DOI 10.1001/archneur.62.9.noc50009; Driver-Dunckley E, 2003, NEUROLOGY, V61, P422; Garcia-Borreguero D, 2003, NEUROLOGY, V61, pS49; Giovannoni G, 2000, J NEUROL NEUROSUR PS, V68, P423, DOI 10.1136/jnnp.68.4.423; Gschwandtner U, 2001, CLIN NEUROPHARMACOL, V24, P170, DOI 10.1097/00002826-200105000-00009; Harbishettar V, 2005, PARKINSONISM RELAT D, V11, P85, DOI 10.1016/j.parkreldis.2004.07.006; Jimenez-Jimenez FJ, 2002, ANN PHARMACOTHER, V36, P1178; KIM SW, 2001, BIOL PSYCHIAT, V49, P28; Kurlan R, 2004, MOVEMENT DISORD, V19, P433, DOI 10.1002/mds.10625; Lawrence AD, 2003, LANCET NEUROL, V2, P595, DOI 10.1016/S1474-4422(03)00529-5; MILNER PM, 1991, CAN J PSYCHOL, V45, P1, DOI 10.1037/h0084275; Molina JA, 2000, MOVEMENT DISORD, V15, P869, DOI 10.1002/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I; Nirenberg MJ, 2006, MOVEMENT DISORD, V21, P524, DOI 10.1002/mds.20757; Ondo W, 2004, ARCH NEUROL-CHICAGO, V61, P1393, DOI 10.1001/archneur.61.9.1393; Pezzella FR, 2005, MOVEMENT DISORD, V20, P77, DOI 10.1002/mds.20288; Riley DE, 2002, CLIN NEUROPHARMACOL, V25, P234, DOI 10.1097/01.WNF.0000017067.78279.83; Roane David M, 2002, Neuropsychiatry Neuropsychol Behav Neurol, V15, P247; Seedat S, 2000, DEPRESS ANXIETY, V11, P185, DOI 10.1002/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H; Serrano-Duenas M., 2002, GER J PSYCHIAT, V5, P62; Sevim S, 2004, J NEUROL NEUROSUR PS, V75, P226; Stein DJ, 2005, CNS SPECTRUMS, V10, P268; Tisch S, 2004, PSYCHIAT CLIN N AM, V27, P757, DOI 10.1016/j.psc.2004.06.004; Trenkwalder C, 2004, CLIN NEUROPHYSIOL, V115, P1975, DOI 10.1016/j.chinph.2004.01.031; UITTI RJ, 1989, CLIN NEUROPHARMACOL, V12, P375, DOI 10.1097/00002826-198910000-00002; Unwin BK, 2000, AM FAM PHYSICIAN, V61, P741; Winkelmann J, 2005, J NEUROL, V252, P67, DOI 10.1007/s00415-005-0604-7
Number of Citaion: 30
Publication: LIPPINCOTT WILLIAMS & WILKINS
City of Publication: PHILADELPHIA
Address of Publication: 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
ISSN: 0362-5664
29-Character Source Abbreviation: CLIN NEUROPHARMACOL
ISO Source Abbreviation: Clin. Neuropharmacol.
Volume: 30
Version: 5
Start of File: 249
End of File: 255
DOI: 10.1097/WNF.0B013E31804C780E
Number of Pages: 7
Web of Science Category: Clinical Neurology; Pharmacology & Pharmacy
Subject Category: Neurosciences & Neurology; Pharmacology & Pharmacy
Document Delivery Number: 216XV
Unique Article Identifier: WOS:000249913200001
- reply : 0
-
- list
-
- prev
- next